Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 10.9% in the afternoon session after the company reported disappointing fourth-quarter results: EPS missed analysts ...

United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by ...

In trading on Wednesday, shares of United Therapeutics Corp (Symbol: UTHR) entered into oversold territory, hitting an RSI reading of 28.5, after changing hands as low as $319.02 per share.

Coming in No. 3 on Fast Company's Queer 50 list, is Martine Rothblatt, the founder and CEO of United Therapeutics. She's also a lawyer, satellite entrepreneur, and futurist. See the innovative ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its GAAP profit of $6.19 per ...

In trading on Wednesday, shares of United Therapeutics Corp (Symbol: UTHR) crossed below their 200 day moving average of $342.02, changing hands as low as $319.02 per share. United Therapeutics ...